Several reports have shown that the relative expression of GAS5 decreases in various types of cancer, such as cervical cancer [43], breast cancer [44], and esophageal squamous cell carcinoma [45], and also in the cisplatin-resistant lung cancer A549 cells [46]. Here, GAS5 is linked to lung cancer.